ENZON PHARM (EZ1.SG)
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon… Read more
ENZON PHARM (EZ1.SG) (EZ1) - Total Liabilities
Latest total liabilities as of September 2025: €44.62 Million EUR
Based on the latest financial reports, ENZON PHARM (EZ1.SG) (EZ1) has total liabilities worth €44.62 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ENZON PHARM (EZ1.SG) - Total Liabilities Trend (2016–2024)
This chart illustrates how ENZON PHARM (EZ1.SG)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ENZON PHARM (EZ1.SG) Competitors by Total Liabilities
The table below lists competitors of ENZON PHARM (EZ1.SG) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IPSEN (I7G.SG)
STU:I7G
|
Germany | €2.50 Billion |
|
Centogene N.V.
NASDAQ:CNTGF
|
USA | $102.44 Million |
|
Patriot Gold Corp
PINK:PGOL
|
USA | $1.60 Million |
|
HANOVER INSURANCE
BE:AF4
|
Germany | €12.49 Billion |
|
iWallet Corporation
PINK:IWAL
|
USA | $694.08K |
|
8COMMON Ltd
AU:8CO
|
Australia | AU$2.65 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down ENZON PHARM (EZ1.SG)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 80.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -48.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ENZON PHARM (EZ1.SG)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ENZON PHARM (EZ1.SG) (2016–2024)
The table below shows the annual total liabilities of ENZON PHARM (EZ1.SG) from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €44.16 Million | -0.08% |
| 2023-12-31 | €44.20 Million | +0.03% |
| 2022-12-31 | €44.18 Million | +3.02% |
| 2021-12-31 | €42.89 Million | +4.93% |
| 2020-12-31 | €40.87 Million | +9562.41% |
| 2019-12-31 | €423.00K | -18.18% |
| 2018-12-31 | €517.00K | +40.49% |
| 2017-12-31 | €368.00K | -60.85% |
| 2016-12-31 | €940.00K | -- |